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Abstract
Background: There is increasing interest in improving understanding of the timing and nature of early
neurodegeneration in Alzheimer’s disease (AD) and developing methods to measure this in vivo. Autosomal
dominant familial Alzheimer’s disease (FAD) provides the opportunity for investigation of presymptomatic change.
We assessed early microstructural breakdown of cortical grey matter in FAD with diffusion-weighted MRI.
Methods: Diffusion-weighted and T1-weighed MRI were acquired in 38 FAD mutation carriers (17 symptomatic, 21
presymptomatic) and 39 controls. Mean diffusivity (MD) was calculated for six cortical regions previously identified
as being particularly vulnerable to FAD-related neurodegeneration. Linear regression compared MD between
symptomatic and presymptomatic carriers and controls, adjusting for age and sex. Spearman coefficients assessed
associations between cortical MD and cortical thickness. Spearman coefficients also assessed associations between
cortical MD and estimated years to/from onset (EYO). Across mutation carriers, linear regression assessed
associations between MD and EYO, adjusting for cortical thickness.
Results: Compared with controls, cortical MD was higher in symptomatic mutation carriers (mean ± SD CDR =
0.88 ± 0.39) for all six regions (p < 0.001). In late presymptomatic carriers (within 8.1 years of predicted symptom
onset), MD was higher in the precuneus (p = 0.04) and inferior parietal cortex (p = 0.003) compared with controls.
Across all presymptomatic carriers, MD in the precuneus correlated with EYO (p = 0.04). Across all mutation carriers,
there was strong evidence (p < 0.001) of association between MD and cortical thickness in all regions except
entorhinal cortex. After adjusting for cortical thickness, there remained an association (p < 0.05) in mutation carriers
between MD and EYO in all regions except entorhinal cortex.
Conclusions: Cortical MD measurement detects microstructural breakdown in presymptomatic FAD and correlates
with proximity to symptom onset independently of cortical thickness. Cortical MD may thus be a feasible biomarker
of early AD-related neurodegeneration, offering additional/complementary information to conventional MRI
measures.
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Background
In Alzheimer’s disease (AD), it has become increas-
ingly important to understand the timing and nature
of neurodegeneration and to develop sensitive
methods for its detection and tracking. Of particular
interest are the changes that characterise very early
disease prior to the onset of clinical symptoms, as
targeting treatments at this stage, before significant ir-
reversible neuronal loss, may provide the greatest
chance of success [1].
Autosomal dominant familial AD (FAD) shares
many features—pathologically, radiologically and clin-
ically—with the more common sporadic form of dis-
ease [2]. Unlike sporadic disease, FAD mutation
carriers have relatively predictable ages at symptom
onset based on family history [3], facilitating the pro-
spective study of asymptomatic individuals prior to
cognitive decline.
Early neurodegeneration involving cortical grey matter
is a recognised feature of both sporadic and familial AD,
with structural MRI identifying similar characteristic
patterns of macrostructural loss within the cerebral cor-
tex [4, 5]. Such cortical thinning predates symptom
onset.
Diffusion-weighted imaging (DWI) allows assess-
ment of changes at the microscopic level, with neur-
onal loss and the breakdown of microstructural
barriers, such as myelin, cell membranes and intracel-
lular organelles, resulting in a measureable difference
in the diffusion of water molecules [6]. Measurement
of such changes may provide additional and/or com-
plementary information to conventional T1-weighted
imaging, with studies suggesting that DWI changes
may be more predictive of early progressive cognitive
change than macrostructural atrophy [7, 8]. While
most DWI studies in AD have focused on white mat-
ter [7, 9–11], it would follow, given the known early
involvement of cortical grey matter [12], that meas-
urement of microstructural DWI changes in the cor-
tex could prove to be valuable in detecting and better
characterising early neuronal breakdown. Grey matter
changes have been found to be more closely related
to clinical decline than those in white matter [13].
In AD, DWI measures of cortical grey matter have been
found to differ between groups of individuals with amnes-
tic MCI who do and do not go on to progress to AD de-
mentia [8]. However, the ability of DWI to detect
presymptomatic cortical changes, and their association
with proximity to symptom onset, remains uncertain. It is
also unclear whether cortical DWI metrics provide any
additional information over and above that given by meas-
urement of cortical thickness.
We used DWI to measure mean diffusivity (MD) in
a group of FAD mutation carriers and non-carrier
controls. MD is a DWI metric that increases with
microstructural breakdown. It assesses diffusion in all
directions and is therefore particularly suited to asses-
sing grey matter, where diffusion is isotropic [14]. We
hypothesised that cortical MD increases presympto-
matically in FAD and correlates with proximity to
symptom onset. Moreover, we aimed to assess the re-
lationship between cortical MD and cortical thickness
and whether measuring microstructural change with
cortical MD provides additional information above
and beyond cortical thickness alone.
Methods
Participants
Seventy-seven participants were recruited to a cohort
study of FAD at the Dementia Research Centre,
University College London: 38 with FAD mutations in
either the presenilin 1 or amyloid precursor protein
genes and 39 healthy controls. Of the mutation car-
riers, 17 had progressive cognitive symptoms and 21
were presymptomatic. All participants underwent clin-
ical assessment, including a semi-structured interview,
neurological examination and completion of the Clin-
ical Dementia Rating scale (CDR) [15]. Estimated
years to/from symptom onset (EYO) was calculated
for the mutation carriers by subtracting the age at
which their parent first developed progressive cogni-
tive symptoms from the participant’s age. Blood sam-
ples were collected from all FAD family members,
with mutation status assessed using Sanger
sequencing.
MRI acquisition
All participants were scanned on the same 3-Tesla Sie-
mens TIM Trio scanner using a 32-channel phased array
head-coil. A sagittal 3D MP-RAGE T1-weighted volu-
metric MRI (echo time/repetition time/inversion time =
2.9/2200/900 ms, dimensions of 256 × 256 × 208, voxel
size of 1.1 mm isotropic) was acquired. Two 64-direction
DWI sequences were acquired with a single shot, spin-
echo echo planar imaging (EPI) sequence (field of view
240 × 240 mm; matrix 96 × 96; yielding a voxel size of
2.5 mm isotropic; 55 contiguous axial slices; repetition
time 6800 ms; echo time 91ms; b value 1000s/mm2). We
acquired nine acquisitions without diffusion weighting
(b = 0 s/mm2).
Image analysis
Cortical parcellation was performed using FreeSurfer
v5.30 (http://surfer.nmr.mgh.harvard.edu). The diffusion-
weighted images were registered to the first b = 0 image
using NiftyReg [16] and corrected for susceptibility [17],
motion and eddy current distortion. The two DWI acqui-
sitions for each participant were combined to increase the
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signal-to-noise ratio, with tensor fitting performed with a
single tensor model using NiftyFit [18] to produce MD
maps.
We restricted our analysis to six cortical regions of
interest (ROIs) identified previously as comprising the
FAD cortical signature [5]: entorhinal cortex, inferior
parietal cortex, precuneus, superior frontal cortex, su-
perior parietal cortex and supramarginal cortex. The
FreeSurfer label (derived from the T1-weighted acqui-
sition) for each cortical ROI was warped from T1 to
diffusion space and registered to the MD map, to
allow extraction of mean MD within that region
(Fig. 1). To reduce potential CSF-grey matter partial
volume effects when calculating regional MD, a
weighted mean was calculated. Weights were derived
from interpolation of the T1 space binarised label
map, which differentiated cortical grey matter from
non-cortex (i.e. white matter or CSF), towards the
lower resolution diffusion space. Cortical thickness for
each region was calculated in FreeSurfer using the
same procedure as described previously [5].
Statistical methods
The presymptomatic mutation carriers were split at
the median EYO (− 8.1 years) into early presymptom-
atic (early PS, i.e. more than 8.1 years before pre-
dicted onset) and late presymptomatic (late PS, i.e.
8.1 years or less before predicted onset), resulting in a
total of four subgroups: controls; early PS; late PS;
and symptomatic. Cortical MD was averaged across
left and right hemispheres. For each ROI, a single lin-
ear regression was used to compare MD between the
four subgroups, adjusting for age and sex. If a global
test provided evidence of a main effect of group, then
post hoc pairwise comparisons between sub-groups
were carried out. Homoskedasticity and normality as-
sumptions concerning residuals were checked and
were not materially violated.
Given non-normal distributions and non-linear rela-
tionships, non-parametric Spearman correlation coeffi-
cients were used to assess the unadjusted association
between EYO and cortical MD in each of the ROIs,
first across all mutation carriers and then in presymp-
tomatic carriers only. Spearman coefficients were also
calculated to assess the association in mutation car-
riers between cortical MD and cortical thickness.
Additionally, in order to investigate whether MD
provides additional information above cortical thick-
ness, in mutation carriers, linear regression assessed
associations between MD and EYO, after adjusting for
cortical thickness. Evidence for a quadratic relation-
ship with EYO was investigated using Wald tests. For
each region, graphs were plotted to show estimated
MD against EYO for a person with the study sample’s
mean cortical thickness for that region. Assumptions
concerning residuals were checked and were not ma-
terially violated.
All analyses used Stata v15 (StataCorp, College Station,
TX, USA). No adjustments were made for multiple test-
ing [19].
Results
Mutation carriers and controls were well matched for
age (42.6 years [SD 9.5] vs 44.6 [9.5]) and sex (15
male/24 female vs 18 male/20 female). The group
demographics, with mutation carriers split between
symptomatic, early PS and late PS, are shown in
Table 1.
Fig. 1 Cortical parcellation and measurement of cortical MD. Each T1 image (a) underwent cortical parcellation using FreeSurfer (v5.30) (b). The FreeSurfer
label for each ROI was warped into diffusion space (c) and registered to the MD map (d) to allow extraction of mean MD within that region (e)
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For each ROI, there was strong evidence (p < 0.0001)
for a main effect of group, so post hoc pairwise compari-
sons were carried out. After adjusting for age and sex,
symptomatic individuals had significantly higher MD
compared to controls, and to both presymptomatic
groups, in all six cortical regions (p < 0.00001 for all, ex-
cept in entorhinal cortex when compared with early PS
(p = 0.03) and with late PS (0.0006)) (Fig. 2, Table 2,
Additional file 1). Cortical MD was higher in the late PS
group compared with controls across all six regions, al-
though this reached statistical significance only in the in-
ferior parietal cortex (estimated adjusted difference in
means 0.34 mm2/s × 10−3, 95% CI 0.12, 0.57; p = 0.003)
and the precuneus (0.28 mm2/s × 10−3, 0.01, 0.55, p =
0.04). No statistically significant differences in MD were
found between the early PS group and controls.
When analysing the MD values, one outlier was identi-
fied (and re-checking the images found no reason to
omit these data). Re-running the regression analyses
without the outlier did not cause any meaningful change
to the results.
Across mutation carriers (n = 36 as EYO was miss-
ing for two symptomatic participants), a positive cor-
relation was found between cortical MD and EYO
(p < 0.0001) in all regions except entorhinal cortex
(p = 0.14), with MD progressively increasing over time.
When including presymptomatic individuals only, the
association between MD and EYO only reached for-
mal statistical significance in the precuneus (Spear-
man’s rho = 0.46, p = 0.04) but a non-significant
positive association was still seen in four of the five
other regions. The one exception was, again, the en-
torhinal cortex, for which during the presymptomatic
period the association between cortical MD and EYO
was estimated to go in the opposite direction
(Table 3).
In mutation carriers (n = 38, no missing values),
cortical MD demonstrated a significant negative
Spearman correlation with cortical thickness (p <
0.0001) in all ROIs except entorhinal cortex (p = 0.24)
(Fig. 3). A similar negative association was found in
non-carriers (rho <− 0.6, p ≤ 0.0005) for all regions ex-
cept entorhinal cortex and superior frontal cortex.
Across mutation carriers (n = 36), a linear regression
of cortical MD against EYO showed that for all six cor-
tical regions there remained a significant association
(p < 0.05) between MD and proximity to symptom onset
after adjusting for cortical thickness (Fig. 4), with MD
estimated to increase over time for individuals with the
same cortical thickness. Removal of the outlier previ-
ously identified led to slightly weaker (p < 0.10) evidence
of an association for three regions (entorhinal, inferior
parietal and precuneus), with the other three (superior
frontal, superior parietal, supramarginal) remaining as
p < 0.05.
Discussion
We found evidence that late presymptomatic FAD muta-
tion carriers (i.e. within 8.1 years of predicted symptom
onset) have significantly increased cortical MD com-
pared with controls in both the precuneus and the infer-
ior parietal cortex. Furthermore, among mutation
carriers, cortical MD was associated with proximity to/
from expected symptom onset, independent of cortical
thickness.
It has previously been shown that cortical diffusivity
differs between AD dementia and controls and between
progressive versus non-progressive MCI [8, 20]. Here,
we also show that MD is higher in those with symptom-
atic AD compared to healthy individuals, in a group of
symptomatic familial AD individuals who on average
were only mildly clinically affected (mean CDR = 0.85).
Furthermore, we showed, albeit with limited statistical
significance, that cortical diffusivity changes were identi-
fiable in presymptomatic FAD a number of years before
the onset of cognitive symptoms, suggesting presymp-
tomatic microstructural cortical breakdown.
Of the six ROIs, the most significant presymptomatic
MD changes were seen in the inferior parietal cortex
and the precuneus. Both of these regions have been
identified as being affected early in AD [4, 5, 21], with
DWI studies in symptomatic AD showing that
Table 1 Participant demographics
N Controls Early presymptomatic Late presymptomatic Symptomatic
39 10 11 17
Age, years (mean (SD)) 44.6 (9.5) 34.8 (5.5)* 41.9 (8.4) 47.6 (9.0)
Gender, m/f 15/24 3/7 5/6 10/7
EYO, years (mean (SD)) – − 11.8 (2.6) − 3.3 (4.6) 4.8 (4.0)^
Global CDR (mean (SD)) 0 0 0 0.85 (0.39)**
For comparison of age, unadjusted linear regression was used; for comparison of CDR, Fisher’s exact test was used
EYO estimated years to onset, CDR Clinical Dementia Rating scale
*Evidence of a difference (p < 0.05) compared with controls
**Evidence of a difference (p < 0.001) compared with controls
^2 missing values
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measurement of precuneus diffusivity allows differenti-
ation between AD-MCI and controls and between AD
and dementia with Lewy bodies [22, 23]. While in five of
the six ROIs cortical MD was positively correlated with
EYO, it was only in the precuneus that we found a sig-
nificant association to persist after removing the symp-
tomatic individuals and focusing on the presymptomatic
participants only. This suggests MD in the precuneus
may closely reflect disease activity in the period ap-
proaching the onset of clinical symptoms.
One previous smaller study also investigated cortical
diffusivity change in presymptomatic FAD [24]. How-
ever, while they too found presymptomatic changes in
the precuneus, they observed a fall in MD rather than an
increase, which was felt possibly to be due to a presymp-
tomatic inflammatory process [25]. A recent small posi-
tron emission tomography study using a tracer for brain
astrocytosis appears to support the possibility of such a
relationship, with astrocytic inflammation decreasing as
cortical diffusivity increased [26]. A further study that
Fig. 2 Box plots of cortical MD in the six regions of interest across the different disease stages. EPS, early presymptomatic; LPS,
late presymptomatic
Table 2 MD values
Controls Early presymptomatic Late presymptomatic Symptomatic
Entorhinal cortex MD (SD) 7.43 (0.52) 7.73 (0.46) 7.50 (0.64) 8.49 (1.03)**
Inferior parietal cortex MD (SD) 7.89 (0.24) 7.93 (0.36) 8.19 (0.26)* 9.26 (0.55)**
Precuneus MD (SD) 8.18 (0.28) 8.07 (0.33) 8.43 (0.42)* 9.50 (0.62)**
Superior frontal cortex MD (SD) 7.98 (0.28) 7.84 (0.22) 7.99 (0.37) 8.89 (0.57)**
Superior parietal cortex MD (SD) 8.34 (0.35) 8.32 (0.35) 8.52 (0.36) 9.58 (0.66)**
Supramarginal cortex MD (SD) 8.04 (0.36) 7.95 (0.36) 8.15 (0.31) 9.24 (0.62)**
Observed mean (SD) MD values (mm2/s × 10−3) are shown for each cortical ROI across the four groups. For comparison of MD, linear regression was used,
adjusted for age and sex
MD mean diffusivity
*Evidence of a difference (p < 0.05) compared with controls
**Evidence of a difference (p < 0.001) compared with controls
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investigated cortical MD in presymptomatic sporadic
AD (diagnosed based on measurement of CSF Aβ) re-
ported a biphasic distribution, with those who had Aβ
pathology but no evidence of neurodegeneration having
reduced MD, but those with both Aβ pathology and
neurodegeneration having increased MD [27]. Interest-
ingly, however, an increase in MD in the precuneus and
inferior parietal cortex—the two regions in our study to
show the earliest rise—did not occur until after symp-
tom onset. Here, in the majority of regions assessed, we
found no evidence to support an initial MD reduction.
The MD increase we observed across multiple regions in
the late presymptomatic group, and the positive associ-
ation with increasing EYO, likely indicate freer diffusion
of water molecules as cellular barriers break down, con-
sistent with what one may expect during a neurodegen-
erative process.
The one region in our study in which MD did not
show significant correlation with disease progression
across the disease spectrum was entorhinal cortex.
For this region, when looking in presymptomatic indi-
viduals only, the association went in the opposite dir-
ection to all other regions, with MD progressively
decreasing with increasing proximity to symptom on-
set. There was greater inter-individual variability in
MD in the entorhinal cortex than in other regions
(Fig. 2), suggesting one explanation for the discrep-
ancy being that the small size and the anatomical lo-
cation of the entorhinal cortex, which can make it
more difficult to parcellate accurately, may mean its
MD signal is particularly vulnerable to CSF contamin-
ation. However, it may also be that, for the presymp-
tomatic period covered by our study, the entorhinal
MD does genuinely behave differently to other re-
gions assessed. This possibility is reflected in the lin-
ear regression model of entorhinal cortex MD as a
function of EYO (adjusted for cortical thickness),
which shows MD in this region initially reducing be-
fore later progressively increasing (Fig. 4). Such an
initial reduction in entorhinal cortex MD would be
consistent with a previous finding from two other
anatomically related regions—the hippocampus and
cingulum—that have also been shown to have early
restriction of diffusion [28].
We found a close association between cortical MD
and cortical thickness in mutation carriers for the
majority of the regions assessed, with increasing cor-
tical MD being associated with decreasing cortical
thickness. Cortical thickness measurement using Free-
Surfer is a widely used and well-validated method of
assessing macrostructural cortical change. The associ-
ation between thickness and MD therefore provides
further face-validity for cortical MD being a marker
of cortical integrity/degeneration, with both reduction
in thickness and increasing MD likely being part of
the same pathological continuum. The fact that an as-
sociation was also present in healthy ageing non-
carriers further supports the idea of both cortical MD
and cortical thickness measuring the same general
characteristic, i.e. neuronal integrity/degeneration (al-
beit different aspects and/or stages), which is known
to progressively alter, although to a lesser extent, in
healthy ageing as well as neurodegenerative disease
[29, 30]. However, importantly, we found that when it
comes to association with disease stage or proximity
to symptom onset (as determined by EYO), cortical
MD shows an association even after adjusting for cor-
tical thickness. This suggests that, rather than provid-
ing directly analogous information to that gained
from cortical thickness alone, the microscopic changes
detected by measuring MD provide independent in-
formation that is of additional value and may reflect
early disease-related neuronal loss. This finding is
consistent with a previous study of AD that assessed
whole brain cortical MD and cortical volume, which
found that while cortical MD showed a trend along
the trajectory from normal controls to MCI to estab-
lished AD dementia, cortical volume did not demon-
strate the same pattern [8]. It is also consistent with
findings from another neurodegenerative disease—
frontotemporal dementia—where it has been found
that differences between patients and controls were
greater for cortical MD than for cortical thickness,
with cortical MD also showing a closer association
with other measures of disease severity [31]. However,
it is difficult to say at present whether the association
between MD and EYO being independent of cortical
thickness means MD tells us something qualitatively
different about what is happening from a neurodegen-
erative perspective or whether it is simply a more
sensitive marker of neurodegeneration. Microstruc-
tural changes such as MD may lie upstream to
macrostructural thickness changes [9, 32], and so
Table 3 Association between MD and EYO in presymptomatic
mutation carriers
Region Correlation with EYO
(Spearman’s rho)
p value
Entorhinal cortex − 0.43 0.05
Inferior parietal cortex 0.28 0.23
Precuneus 0.46 0.04
Superior frontal cortex 0.40 0.07
Superior parietal cortex 0.32 0.16
Supramarginal cortex 0.11 0.63
Spearman correlation coefficients and p values for the association between
MD and EYO in presymptomatic mutation carriers only, in each of the six
cortical regions of interest
EYO estimated years to onset
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could provide an earlier measure of change. Further
studies, ideally with longitudinal assessment, will be
required to confirm this.
Limitations
This study has a number of limitations. The sample
size was limited by the relative rarity of FAD, al-
though to our knowledge, this is the largest DWI
study of FAD to date. As each group represents a dif-
ferent disease stage, their average ages differed;
however, we adjusted for age in the group compari-
sons. Although steps were taken to minimise the ef-
fects of partial volume, with our data (not presented
here) showing that the correction made led to a sig-
nificant reduction in partial volume effects, this can-
not be eliminated completely. Additionally, while
parental age at onset has been shown to correlate
closely with actual age at onset, it remains a proxy
measure [3]. Finally, the current study includes cross-
sectional data only, meaning that it is not possible
Fig. 3 Association between cortical mean diffusivity and cortical thickness. Scatter plots are shown, with accompanying Spearman correlation
coefficients, for the association between mean diffusivity and cortical thickness across mutation carriers. Black dots represent symptomatic carriers
and white dots presymptomatic carriers
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directly to assess association between MD and disease
progression; assessment in future longitudinal studies of
whether early microstructural loss as measured by MD is
associated with rate of subsequent decline will be valuable.
Conclusions
We have demonstrated that measurement of cortical
MD is able to detect presymptomatic microstructural
breakdown of the cerebral cortex in FAD and is associ-
ated with proximity to symptom onset independently of
cortical thickness. Cortical MD may therefore provide
complementary information to macrostructural atrophy.
Our findings support the further investigation of cortical
MD, particularly within the precuneus and inferior par-
ietal cortex, as a potential marker of early AD
neurodegeneration.
Fig. 4 Relationship between mean diffusivity and estimated years to/from symptom onset in mutation carriers. Graphs show linear regression of
MD against EYO after adjusting for cortical thickness and including a quadratic term for EYO in all models for consistency. For each region,
cortical thickness was set at the mean value for the study sample for that region: entorhinal (2.75 mm), inferior parietal (2.20 mm), precuneus
(2.14 mm), superior frontal (2.32 mm), superior parietal (1.91 mm) and supramarginal (2.30 mm). The p value is from a test of the association
between MD and EYO after adjusting for cortical thickness. MD, mean diffusivity; EYO, estimated years to/from symptom onset
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